An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Fulgent Genetics (NASDAQ: FLGT) will announce its fourth quarter and full year 2021 financial results on February 23, 2022, after market close. Following this, a conference call with the company's top executives will be held at 4:30 PM ET to discuss the results. Investors can access the call via a live audio webcast on the company’s website or by phone. Fulgent is focused on genetic testing across various sectors, leveraging its technology platform to provide high-quality, flexible, and competitively priced testing services.
Positive
None.
Negative
None.
TEMPLE CITY, Calif.--(BUSINESS WIRE)--
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Wednesday February 23, 2022. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief Commercial Officer Brandon Perthuis, and Chief Medical Officer Dr. Larry Weiss will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (888) 394-8218 using the confirmation code 4130266. An audio replay will be available in the Investors section of the company’s website.
About Fulgent Genetics
Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing with its technology platform, Fulgent performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of our business is our ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.
Investor Relations Contact:
The Blueshirt Group Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com
Source: Fulgent Genetics, Inc.
FAQ
When will Fulgent Genetics release its Q4 2021 financial results?
Fulgent Genetics will release its Q4 2021 financial results on February 23, 2022, after the market closes.
What time is the conference call for Fulgent Genetics' Q4 2021 results?
The conference call will take place at 4:30 PM ET on February 23, 2022.
How can I access the conference call for Fulgent Genetics?
You can access the conference call through a live audio webcast on Fulgent Genetics' Investors website or by dialing (888) 394-8218 with the confirmation code 4130266.
Who will be presenting during Fulgent Genetics' financial results call?
The call will feature Fulgent's Chairman and CEO Ming Hsieh, CFO Paul Kim, CCO Brandon Perthuis, and CMO Dr. Larry Weiss.
What is Fulgent Genetics' focus in the genetic testing market?
Fulgent Genetics focuses on transforming patient care in oncology, infectious diseases, rare diseases, and reproductive health through its advanced genetic testing technologies.
